The UK and US have reached a landmark commercial pact that will preserve zero duties on UK drug shipments being sold in the American market.
The Terms of the Deal
As part of the deal, the UK has pledged to raise spending on drugs through the National Health Service (NHS). This commitment ensures that duties on these vital products will remain at nothing for a period of the next three years.
This deal comes after recent statements to significantly raise duties on branded drug products, with potential rates floated reaching double the cost.
"This agreement between the UK strengthens the international landscape for cutting-edge drugs and establishes much-needed balance to U.S.–U.K. pharmaceutical trade," a release declared.
Commercial Impact
Medicines represent one of the UK's most significant export categories to the United States, which is by far the largest buyer for leading UK drugmakers.
Export figures reveal that in the one-year period prior to the third quarter, the UK exported medicines worth £11.1bn to the US. This amount accounted for nearly one-fifth of all goods exports in that timeframe.
"This guarantee secures work, stimulates funding and facilitates the UK to emerge as a worldwide center for life sciences," a government official remarked.
Specific British Pledges
The deal involves several specific pledges from the British government:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new medicines to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to increase overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum drug companies must refund to the NHS to control costs will be limited at 15%. In the past, refunds were more than 20%.
Broader Context
The pact follows a long-running tension between the pharmaceutical industry and the British authorities over spending levels and approval rates.
The disagreement were exacerbated by assertions that US consumers were charged significantly more for the equivalent treatments than patients in the other developed nations.
Recently, several major drug company projects in the UK have been paused or cancelled, while multi-billion-dollar investments have been pledged toward American operations.
One official stated that the NHS had to spend more on medicines, noting that its expenditure on drugs had decreased as a share of its resources over the previous ten-year period.
